miR-567对非小细胞肺癌细胞恶性生物学行为及吉非替尼耐药的影响

李静, 李海洋, 赵振山

李静, 李海洋, 赵振山. miR-567对非小细胞肺癌细胞恶性生物学行为及吉非替尼耐药的影响[J]. 广西医科大学学报, 2023, 40(3): 420-426. DOI: 10.16190/j.cnki.45-1211/r.2023.03.012
引用本文: 李静, 李海洋, 赵振山. miR-567对非小细胞肺癌细胞恶性生物学行为及吉非替尼耐药的影响[J]. 广西医科大学学报, 2023, 40(3): 420-426. DOI: 10.16190/j.cnki.45-1211/r.2023.03.012
Li Jing, Li Haiyang, Zhao Zhenshan. Effect of miR-567 on malignant biological behavior and gefitinib resistance of non-small cell lung cancer cells[J]. Journal of Guangxi Medical University, 2023, 40(3): 420-426. DOI: 10.16190/j.cnki.45-1211/r.2023.03.012
Citation: Li Jing, Li Haiyang, Zhao Zhenshan. Effect of miR-567 on malignant biological behavior and gefitinib resistance of non-small cell lung cancer cells[J]. Journal of Guangxi Medical University, 2023, 40(3): 420-426. DOI: 10.16190/j.cnki.45-1211/r.2023.03.012

miR-567对非小细胞肺癌细胞恶性生物学行为及吉非替尼耐药的影响

基金项目: 

河北省医学科学研究课题计划(No.20221570)

详细信息
    通讯作者:

    赵振山,E-mail:zhaovip6@163.com

  • 中图分类号: R394.6

Effect of miR-567 on malignant biological behavior and gefitinib resistance of non-small cell lung cancer cells

  • 摘要   目的:探究miR-567 对非小细胞肺癌(NSCLC)的生物学功能以及吉非替尼耐药性的影响。方法:采用RT-qPCR 检测miR-567 在人肺上皮细胞系BEAS-2B、NSCLC 细胞系(PC9、HCC827、A549、NCI-H1975)以及吉非替尼耐药细胞株PC9/GR 中的表达。PC9 细胞和PC9/GR 细胞分别分为negative control 组、miR-567 mimic 组、miR-567 inhibitor 组和miR-567 mimic+CDK8 组,CCK8 检测细胞的增殖能力,Transwell 法检测细胞迁移和侵袭能力,双荧光素酶报告基因实验检测miR-567 与CDK8 的靶向关系,western blotting 检测细胞中CDK8 的表达。结果:miR-567 在PC9、HCC827、A549、NCI-H1975 中的表达显著低于BEAS-2B,miR-567 在PC9/GR 细胞中的表达显著低于PC9。相比于negative control 组,miR-567 mimic 组PC9 细胞增殖、迁移和侵袭能力均显著减弱(P<0.05)。miR-567 inhibitor 组PC9 细胞增殖、迁移和侵袭能力均显著增强(P<0.05),miR-567 mimic 组PC9/GR 细胞增殖率显著低于negative control 组(P<0.05)。miR-567 inhibitor 组PC9/GR 细胞增殖率显著高于negative control组(P<0.05)。双荧光素酶报告实验和western blotting检测结果显示CDK8为miR-567的靶基因。相比于miR-567 mimic 组,miR-567 mimic+CDK8 组PC9 细胞的增殖、迁移以及侵袭能力均显著增强(P<0.05),miR-567 mimic+CDK8 组PC9/GR 细胞增殖率显著升高(P<0.01)。结论:miR-567 可通过靶向调控CDK8 而抑制NSCLC 细胞的增殖、迁移和侵袭能力以及吉非替尼耐药。
    Abstract   Objective: To explore the effect of miR-567 on the biological function and gefitinib resistance of nonsmall cell lung cancer (NSCLC).Methods: Real-time fluorescence quantitative polymerase chain reaction (RTqPCR)was used to detect the expressions of miR-567 in human lung epithelial cell line BEAS-2B, non-small cell lung cancer cell line PC9, HCC827, A549, NCI-H1975, and gefitinib-resistant cell line PC9/GR.PC9 cells and PC9/GR cells were divided into negative control group, miR-567 mimic group, miR-567 inhibitor group and miR-567 mimic+CDK8 group, respectively.Cell proliferation ability was detected by CCK8 method, the migration and invasion ability of cells were detected by Transwell cell assay, the targeting relationship between miR-567 and CDK8 was detected by double luciferase reporter gene assay, and the expression of CDK8 in cells was detected by western blotting.Results: The expression of miR-567 in PC9, HCC827, A549 and NCI-H1975 was significantly lower than that in BEAS-2B, and the expression of miR-567 in PC9/GR cells was significantly lower than that in PC9.Compared with negative control group, proliferation, migration and invasion ability of PC9 cells in miR-567 mimic group significantly decreased (P<0.05) and those in miR-567 inhibitor group significantly increased (P<0.05).The proliferation rate of PC9/GR cells in miR-567 mimic group was significantly lower than that in negative control group (P<0.05), and the proliferation rate of PC9/GR cells in miR-567 inhibitor group was significantly higher than that in negative control group (P<0.05).Double luciferase assay and western blotting analysis showed that CDK8 was the target gene of miR-567.Compared with miR-567 mimic group, proliferation, migration and invasion ability of PC9 cells in miR-567 mimic+CDK8 group significantly increased (P<0.05), and the proliferation rate of PC9/GR cells significantly increased (P<0.01).Conclusion: miR-567 can inhibit proliferation, migration, invasion and gefitinib resistance of non-small cell lung cancer cells by targeting CDK8 regulation.
  • 期刊类型引用(1)

    1. 董立慧,张之君,侯翠芳. 微RNA对非小细胞肺癌程序性死亡蛋白1抑制剂联合同步化疗疗效的预测价值. 华西医学. 2024(01): 36-41 . 百度学术

    其他类型引用(0)

计量
  • 文章访问数:  42
  • HTML全文浏览量:  0
  • PDF下载量:  4
  • 被引次数: 1
出版历程
  • 收稿日期:  2022-11-18
  • 网络出版日期:  2024-01-31

目录

    /

    返回文章
    返回
    x 关闭 永久关闭